{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:08:19Z","timestamp":1777396099155,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,10,25]]},"abstract":"<jats:p>Background: The ATN scheme was proposed as an unbiased biological characterization of the Alzheimer\u2019s disease (AD) spectrum, grouping biomarkers into three categories: brain Amyloidosis-A, Tauopathy-T, Neurodegeneration-N. Although this scheme was mainly recommended for research, it is relevant for diagnosis. Objective: To evaluate the ATN scheme performance in real-life cohorts reflecting the inflow of patients with cognitive complaints and different underlying disorders in general neurological centers. Methods: We included patients (n\u200a=\u200a1,128) from six centers with their core cerebrospinal fluid-AD biomarkers analyzed centrally. A was assessed through A\u03b242\/A\u03b240, T through pTau-181, and N through tTau. Association between demographic features, clinical diagnosis at baseline\/follow-up and ATN profiles was assessed. Results: The prevalence of ATN categories was: A-T-N-: 28.3%; AD continuum (A\u200a+\u200aT-\/+N-\/+): 47.8%; non-AD (A- plus T or\/and N+): 23.9%. ATN profiles prevalence was strongly influenced by age, showing differences according to gender, APOE genotype, and cognitive status. At baseline, 74.6% of patients classified as AD fell in the AD continuum, decreasing to 47.4% in mild cognitive impairment and 42.3% in other neurodegenerative conditions. At follow-up, 41% of patients changed diagnosis, and 92% of patients that changed to AD were classified within the AD continuum. A\u200a+\u200awas the best individual marker for predicting a final AD diagnosis, and the combinations A\u200a+\u200aT+ (irrespective of N) and A\u200a+\u200aT+N+ had the highest overall accuracy (83%). Conclusion: The ATN scheme is useful to guide AD diagnosis in real-life neurological centers settings. However, it shows a lack of accuracy for patients with other types of dementia. In such cases, the inclusion of other markers specific for non-AD proteinopathies could be an important aid to the differential diagnosis.<\/jats:p>","DOI":"10.3233\/jad-220587","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T13:57:06Z","timestamp":1663336626000},"page":"419-432","source":"Crossref","is-referenced-by-count":8,"title":["Alzheimer\u2019s Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers"],"prefix":"10.1177","volume":"90","author":[{"given":"In\u00eas","family":"Baldeiras","sequence":"first","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Anuschka","family":"Silva-Sp\u00ednola","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Marisa","family":"Lima","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"},{"name":"Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences, University of Coimbra, Coimbra, Portugal"}]},{"given":"Maria Jo\u00e3o","family":"Leit\u00e3o","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Jo\u00e3o","family":"Dur\u00e3es","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Daniela","family":"Vieira","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"}]},{"given":"Miguel","family":"T\u00e1buas-Pereira","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Vitor Tedim","family":"Cruz","sequence":"additional","affiliation":[{"name":"ULSM Unidade Local de S\u00e1ude de Matosinhos, Matosinhos, Portugal"}]},{"given":"Raquel","family":"Rocha","sequence":"additional","affiliation":[{"name":"ULSM Unidade Local de S\u00e1ude de Matosinhos, Matosinhos, Portugal"}]},{"given":"Luisa","family":"Alves","sequence":"additional","affiliation":[{"name":"Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"}]},{"given":"\u00c1lvaro","family":"Machado","sequence":"additional","affiliation":[{"name":"Hospital de Braga, Braga, Portugal"}]},{"given":"Miguel","family":"Milheiro","sequence":"additional","affiliation":[{"name":"Hospital de Faro, Faro, Portugal"}]},{"given":"Beatriz","family":"Santiago","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Baixo Vouga, Aveiro, Portugal"}]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"},{"name":"Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220587_ref1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: A systematic review and meta-analysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","article-title":"Age and sex specific prevalences of cerebral \u03b2-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50\u201395 years: A cross-sectional study","volume":"16","author":"Jack","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220587_ref5","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","article-title":"Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer\u2019s disease pathophysiology (SNAP) or Alzheimer\u2019s disease pathology: A longitudinal study","volume":"15","author":"Burnham","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220587_ref7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jalz.2019.05.006","article-title":"Frequency and longitudinal clinical outcomes of Alzheimer\u2019s AT(N) biomarker profiles: A longitudinal study","volume":"15","author":"Yu","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref9","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","article-title":"ATN classification and clinical progression in subjective cognitive decline. The SCIENCe project","volume":"95","author":"Ebenau","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref10","first-page":"e12031","article-title":"Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders","volume":"13","author":"Eckerstr\u00f6m","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220587_ref12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000008361","article-title":"Applying the ATN scheme in a memory clinic population. The ABIDE project","volume":"93","author":"Altomare","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3233\/JAD-191227","article-title":"The Amyloid, Tau, and Neurodegeneration (A\/T\/N) classification applied to a clinical research cohort with long-term follow-Up","volume":"74","author":"Gr\u00f8ntvedt","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220587_ref14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13195-021-00817-4","article-title":"Prognostic value of amyloid\/tau\/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer\u2019s disease","volume":"13","author":"Delmotte","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220587_ref15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.3233\/JAD-220587_ref19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"Roman","year":"1993","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"Mckeith","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220587_ref23","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019sdisease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220587_ref24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220587_ref25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref27","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"key":"10.3233\/JAD-220587_ref28","first-page":"1","article-title":"The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) external cause-of-injury framework for categorizing mechanism and intent of injury","volume":"136","author":"Hedegaard","year":"2019","journal-title":"Natl Health Stat Rep"},{"key":"10.3233\/JAD-220587_ref29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark Med"},{"key":"10.3233\/JAD-220587_ref30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-018-0362-2","article-title":"Addition of the A\u03b242\/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer\u2019s disease dementia in mild cognitive impairment","volume":"10","author":"Baldeiras","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220587_ref31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of theLumipulse G cerebrospinal fluid assays for routine diagnosis ofAlzheimer\u2019s disease","volume":"11","author":"Leit\u00e3o","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220587_ref32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/CIA.S294756","article-title":"Application of cerebrospinal fluid AT(N) framework on the diagnosis of ad and related cognitive disorders in Chinese Han population","volume":"16","author":"Ye","year":"2021","journal-title":"Clin Intervent Aging"},{"key":"10.3233\/JAD-220587_ref34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol Neurodegen"},{"key":"10.3233\/JAD-220587_ref35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias","volume":"92","author":"Alcolea","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-220587_ref36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3233\/JAD-180240","article-title":"Distribution of cerebrospinal fluid biomarker profiles in patients explored for cognitive disorders","volume":"6","author":"Paquet","year":"2018","journal-title":". J Alzheimers Dis"},{"key":"10.3233\/JAD-220587_ref37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archpsyc.55.9.809","article-title":"The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis","volume":"55","author":"Gao","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"10.3233\/JAD-220587_ref38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220587_ref39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): A common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220587_ref41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.arr.2017.02.003","article-title":"Suspected non-Alzheimer\u2019s pathology \u2013Is it non-Alzheimer\u2019s or non-amyloid?","volume":"36","author":"Dani","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-220587_ref42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.dadm.2019.01.001","article-title":"Frontotemporal dementia is the leading cause of \u201ctrue\u201dA-\/T+profiles defined with Ab42\/40 ratio","volume":"11","author":"Pouclet-Courtemanche","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-220587_ref43","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00415-016-8209-x","article-title":"CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt\u2013Jakob disease suspected cases with inconclusive 14-3-3 result","volume":"263","author":"Leit\u00e3o","year":"2016","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220587_ref44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2020.11.016","article-title":"Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems","volume":"82","author":"Constantinides","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JAD-220587_ref45","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awaa165","article-title":"ATN status in amnestic and non-amnestic Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"143","author":"Cousins","year":"2020","journal-title":"Brain"},{"key":"10.3233\/JAD-220587_ref46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/alz.12233","article-title":"ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration","volume":"17","author":"Cousins","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220587_ref47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","article-title":"Cognitive and neuroimaging features and brain \u03b2-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): A longitudinal observational study","volume":"17","author":"Dubois","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220587_ref48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/gps.5427","article-title":"Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer\u2019s disease consortium survey","volume":"36","author":"Frederiksen","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220587_ref49","doi-asserted-by":"crossref","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","article-title":"The implications of different approaches to define AT(N) in Alzheimer\u2019s disease","volume":"94","author":"Mattsson-Carlgren","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-220587_ref50","doi-asserted-by":"crossref","first-page":"718959","DOI":"10.3389\/fnagi.2021.718959","article-title":"Optimal combinations of AT(N) biomarkers to determine longitudinal cognition in the Alzheimer\u2019s disease","volume":"13","author":"Lin","year":"2021","journal-title":". Front Aging Neurosci"},{"key":"10.3233\/JAD-220587_ref51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220587_ref52","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3233\/JAD-210236","article-title":"Taking the A train? Limited consistency of Abeta42 and the Abeta42\/40 Ratio in the AT(N) classification","volume":"83","author":"Gouilly","year":"2021","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:30Z","timestamp":1777370850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":51,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-220587","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}